Penumbra (Penumbra) Net Margin %

: 19.05% (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

Net margin is calculated as Net Income divided by its Revenue. Penumbra's Net Income for the three months ended in Dec. 2023 was $54 Mil. Penumbra's Revenue for the three months ended in Dec. 2023 was $285 Mil. Therefore, Penumbra's net margin for the quarter that ended in Dec. 2023 was 19.05%.

The historical rank and industry rank for Penumbra's Net Margin % or its related term are showing as below:

PEN' s Net Margin % Range Over the Past 10 Years
Min: -2.8 Med: 1.44 Max: 8.85
Current: 8.59

PEN's Net Margin % is ranked better than
69.32% of 818 companies
in the Medical Devices & Instruments industry
Industry Median: 0.045 vs PEN: 8.59

Penumbra Net Margin % Historical Data

The historical data trend for Penumbra's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Penumbra Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Margin %

8.85

-2.80

0.71

-0.24

8.59

Penumbra Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Margin %																1.75	3.55	7.25	3.40	19.05

Competitive Comparison

For the Medical Devices subindustry, Penumbra's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Penumbra Net Margin % Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Penumbra's Net Margin % distribution charts can be found below:

* The bar in red indicates where Penumbra's Net Margin % falls into.

Penumbra Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Penumbra's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	90.954	/	1058.522
	=	8.59 %

Penumbra's Net Margin for the quarter that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	54.218	/	284.679
	=	19.05 %

Penumbra (NYSE:PEN) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Penumbra Net Margin % Related Terms

Thank you for viewing the detailed overview of Penumbra's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Penumbra (Penumbra) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Penumbra Inc (NYSE:PEN) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

PEN:Mexico 0P8:Germany

Address

One Penumbra Place, Alameda, CA, USA, 94502

Website

https://www.penumbrainc.com

Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are primarily sold to hospitals and are developed for use by specialist physicians. The neurovascular product category contributes to the majority of revenue. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. Penumbra generates the majority of its revenue in the United States.

Executives

Harpreet Grewal	director	C/O VISTAPRINT USA, INCORPORATED, 100 HAYDEN AVE., LEXINGTON MA 02050
Surbhi Sarna	director	ONE PENUMBRA PLACE, ALAMEDA CA 94502
Johanna Roberts	officer: EVP, Gen. Counsel & Secretary	PENUMBRA, INC., ONE PENUMBRA PLACE, ALAMEDA CA 94502
Bridget O'rourke	director	ONE PENUMBRA PLACE, ALAMEDA CA 94502
Adam Elsesser	director, officer: Chairman, CEO and President	1351 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Don W. Kassing	director	1351 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Thomas Wilder	director	2 MUSICK, IRVINE CA 92618
Arani Bose	director, officer: Chief Innovator	1351 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Lynn Rothman	officer: EVP and Chief Business Officer	1351 HARBOR BAY PARKWAY, ALAMEDA CA 94502
James Robert Pray	officer: President, International	1351 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Sridhar Kosaraju	officer: CFO and Head of Strategy	1351 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Maggie Yuen	officer: Chief Financial Officer	ONE PENUMBRA PLACE, ALAMEDA CA 94502
Lambert Shiu	officer: Chief Accounting Officer	ONE PENUMBRA PLACE, ALAMEDA CA 94502
Janet Leeds	director	ONE PENUMBRA PLACE, ALAMEDA CA 94502
Robert D. Evans	officer: EVP, Gen. Counsel & Secretary	ONE PENUMBRA PLACE, 1351 HARBOR BAY PARKWAY, ALAMEDA CA 94502